Literature DB >> 12631672

Measurement and determinants of the natural history of liver fibrosis in hepatitis C virus infection: a cross sectional and longitudinal study.

M Wright1, R Goldin, A Fabre, J Lloyd, H Thomas, C Trepo, P Pradat, M Thursz.   

Abstract

INTRODUCTION: The rate of development of liver fibrosis in hepatitis C virus (HCV) infection varies between individuals. This accounts for the variation in duration of progression to cirrhosis. The aims of this study were: (1) to determine whether fibrosis progresses linearly through the grading scales and (2) to identify factors which influence the rate of fibrosis.
METHODS: HCV infected patients who had undergone at least one liver biopsy were identified. Biopsies were scored using the modified HAI (Ishak) and METAVIR systems, which were compared. Patients were treatment naïve at first biopsy. Demographic features were examined for their relationship to fibrosis rate (defined as fibrosis stage/infection duration) using univariate and multivariate analysis. A subgroup of patients with two biopsies was examined to test the assumption that fibrosis progresses in a linear fashion.
RESULTS: A total of 917 patients were included. Male sex (p<0.00001), older age at infection (p</=0.00001), and viral genotype non-1 (p=0.005) were all associated with a rapid rate of fibrosis. On multiple linear regression they accounted for 29.5% of the variability in fibrosis rate (r(2)=0.295). METAVIR and Ishak scores were highly correlated (r=0.935, p<0.0001). In 137 patients who had two biopsies, the predicted probability for an increase of 1 on the fibrosis score was too low to assess linearity.
CONCLUSIONS: Demographic features account for a minority of fibrosis rate variability. The Ishak and METAVIR scoring systems are equivalent. Linearity of fibrosis progression cannot be assessed in biopsies only a few years apart.

Entities:  

Mesh:

Year:  2003        PMID: 12631672      PMCID: PMC1773621          DOI: 10.1136/gut.52.4.574

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  16 in total

1.  Accuracy of staging in primary biliary cirrhosis.

Authors:  M C Garrido; S G Hubscher
Journal:  J Clin Pathol       Date:  1996-07       Impact factor: 3.411

2.  The management of chronic hepatitis C virus infection.

Authors:  J C Booth; J L Brown; H C Thomas
Journal:  Gut       Date:  1995-10       Impact factor: 23.059

Review 3.  Histological grading and staging of chronic hepatitis.

Authors:  K Ishak; A Baptista; L Bianchi; F Callea; J De Groote; F Gudat; H Denk; V Desmet; G Korb; R N MacSween
Journal:  J Hepatol       Date:  1995-06       Impact factor: 25.083

Review 4.  Classification of chronic hepatitis: diagnosis, grading and staging.

Authors:  V J Desmet; M Gerber; J H Hoofnagle; M Manns; P J Scheuer
Journal:  Hepatology       Date:  1994-06       Impact factor: 17.425

5.  Management of chronic hepatitis C: clinical audit of biopsy based management algorithm.

Authors:  G R Foster; R D Goldin; J Main; I Murray-Lyon; S Hargreaves; H C Thomas
Journal:  BMJ       Date:  1997-08-23

6.  Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups.

Authors:  T Poynard; P Bedossa; P Opolon
Journal:  Lancet       Date:  1997-03-22       Impact factor: 79.321

7.  Quantitative versus morphological assessment of liver fibrosis: semi-quantitative scores are more robust than digital image fibrosis area estimation.

Authors:  Mark Wright; Mark Thursz; Rebecca Pullen; Howard Thomas; Robert Goldin
Journal:  Liver Int       Date:  2003-02       Impact factor: 5.828

8.  Long-term mortality after transfusion-associated non-A, non-B hepatitis. The National Heart, Lung, and Blood Institute Study Group.

Authors:  L B Seeff; Z Buskell-Bales; E C Wright; S J Durako; H J Alter; F L Iber; F B Hollinger; G Gitnick; R G Knodell; R P Perrillo
Journal:  N Engl J Med       Date:  1992-12-31       Impact factor: 91.245

9.  Clinical outcomes after transfusion-associated hepatitis C.

Authors:  M J Tong; N S el-Farra; A R Reikes; R L Co
Journal:  N Engl J Med       Date:  1995-06-01       Impact factor: 91.245

10.  Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group.

Authors: 
Journal:  Hepatology       Date:  1994-07       Impact factor: 17.425

View more
  32 in total

1.  A polymorphism that delays fibrosis in hepatitis C promotes alternative splicing of AZIN1, reducing fibrogenesis.

Authors:  Andrew J Paris; Zohar Snapir; Cindy D Christopherson; Shirley Y Kwok; Ursula E Lee; Zahra Ghiassi-Nejad; Peri Kocabayoglu; John J Sninsky; Josep M Llovet; Chaim Kahana; Scott L Friedman
Journal:  Hepatology       Date:  2011-12       Impact factor: 17.425

2.  Iron, haemochromatosis and thalassaemia as risk factors for fibrosis in hepatitis C virus infection.

Authors:  Mark Thursz
Journal:  Gut       Date:  2007-05       Impact factor: 23.059

Review 3.  Liver transplantation for hepatitis C virus related liver disease.

Authors:  I Gee; G Alexander
Journal:  Postgrad Med J       Date:  2005-12       Impact factor: 2.401

Review 4.  Hepatitis C: cost of illness and considerations for the economic evaluation of antiviral therapies.

Authors:  John B Wong
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

5.  Systematic Review of Health State Utility Values Used in European Pharmacoeconomic Evaluations for Chronic Hepatitis C: Impact on Cost-Effectiveness Results.

Authors:  Ru Han; Clément François; Mondher Toumi
Journal:  Appl Health Econ Health Policy       Date:  2021-01       Impact factor: 2.561

6.  The healthcare burden imposed by liver disease in aging Baby Boomers.

Authors:  Gary L Davis; William L Roberts
Journal:  Curr Gastroenterol Rep       Date:  2010-02

7.  Factor V Leiden polymorphism and the rate of fibrosis development in chronic hepatitis C virus infection.

Authors:  M Wright; R Goldin; S Hellier; S Knapp; A Frodsham; B Hennig; A Hill; R Apple; S Cheng; H Thomas; M Thursz
Journal:  Gut       Date:  2003-08       Impact factor: 23.059

8.  Fibrosis progression in African Americans and Caucasian Americans with chronic hepatitis C.

Authors:  Norah A Terrault; Kelly Im; Ross Boylan; Peter Bacchetti; David E Kleiner; Robert J Fontana; Jay H Hoofnagle; Steven H Belle
Journal:  Clin Gastroenterol Hepatol       Date:  2008-08-19       Impact factor: 11.382

9.  Interleukin-10 promoter polymorphisms and the outcome of hepatitis C virus infection.

Authors:  Susanne Knapp; Branwen J W Hennig; Angela J Frodsham; Lyna Zhang; Simon Hellier; Mark Wright; Rob Goldin; Adrian V S Hill; Howard C Thomas; Mark R Thursz
Journal:  Immunogenetics       Date:  2003-08-26       Impact factor: 2.846

10.  Role of host genetics in fibrosis.

Authors:  Georgina L Hold; Paraskevi Untiveros; Karin A Saunders; Emad M El-Omar
Journal:  Fibrogenesis Tissue Repair       Date:  2009-12-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.